CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/analyzing-key-data-from-lag3-combinations-in-the-treatment-of-metastatic-melanoma/24364/This activity focuses on improving clinician a

What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage III/IV Melanoma

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/what-dermatologists-surgeons-need-to-know-adjuvant-treatment-for-resectable-stage-iiiiv-melanoma/24380/This educational initiative wil

Case Consult: Adjuvant Therapy Following Localized Treatment for Stage III Melanoma

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/case-consult-adjuvant-therapy-following-localized-treatment-for-stage-iii-melanoma/24381/This educational initiative will enhance derm

Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/optimizing-therapeutic-selection-for-a-patient-with-newly-diagnosed-braf-v600e-mutated-metastatic-melanoma/24365/This activity focuses

Navigating Adjuvant ICI Treatment in Stage II Melanoma: A Patient Case Presentation

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/navigating-adjuvant-ici-treatment-in-stage-ii-melanoma-a-patient-case-presentation/24379/This educational initiative will enhance derm

First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/first-line-treatment-of-metastatic-melanoma-after-adjuvant-anti-pd-1/24366/This activity focuses on improving clinician awareness and

Analyzing Key Data from LAG-3 Combinations in the Treatment of Metastatic Melanoma

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/analyzing-key-data-from-lag-3-combinations-in-the-treatment-of-metastatic-melanoma/24364/This activity focuses on improving clinician

Future Directions: Targeting LAG-3 in Melanoma Treatment

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/future-directions-targeting-lag-3-in-melanoma-treatment/24369/This activity focuses on improving clinician awareness and knowledge of

Managing Immunotherapy-Related Adverse Events during Adjuvant Treatment for Resectable Melanoma

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/managing-immunotherapy-related-adverse-events-during-adjuvant-treatment-for-resectable-melanoma/24382/This educational initiative will

Future Directions: Targeting LAG3 in Melanoma Treatment

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/future-directions-targeting-lag3-in-melanoma-treatment/24369/This activity focuses on improving clinician awareness and knowledge of L

Optimizing Resectable Melanoma Outcomes Through Multidisciplinary Care and Multimodal Treatment Strategies

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/optimizing-resectable-melanoma-outcomes-through-multidisciplinary-care-and-multimodal-treatment-strategies/24383/This educational init

Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-related-adverse-effects-in-lag-3-combination-ici-therapy-for-metastatic-melanoma/24367/This activity focuses on i

What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage II Melanoma

3 days ago

Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/unlocking-synergy-exploring-the-interaction-between-lag-3-and-other-immune-checkpoints/24363/This activity focuses on improving clinic

Navigating Treatment-Related Adverse Effects in LAG3 Combination ICI Therapy for Metastatic Melanoma

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-related-adverse-effects-in-lag3-combination-ici-therapy-for-metastatic-melanoma/24367/This activity focuses on im

Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status

3 days ago

CME credits: 0.75Valid until: 26-04-2025Claim your CME credit at https://reachmd.com/programs/cme/patient-case-tailoring-first-line-treatment-for-a-patient-with-metastatic-melanoma-and-impaired-performance-status/24368/This activity

Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints

3 days ago

Host: Hussein Tawbi, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3

Experts on Call: Connecting Specialists and PCPs to Improve Patient-Centered Obesity Management

4 days ago

Host: Robert F. Kushner, MD Host: Donna Ryan, MD Host: Christopher D. Still, DO, FACN, FACP, FTOS Obesity experts review obesity management strategies and provide insight on best practices for implementation in a primary c

Experts on the Ground: Data Updates on Emerging Therapies for IgAN

4 days ago

CME credits: 0.25Valid until: 12-11-2024Claim your CME credit at https://reachmd.com/programs/cme/experts-on-the-ground-data-updates-on-emerging-therapies-for-igan/24045/Expert Nephrologist Richard Lafayette, MD, FACP, gives an over

On the Clinic Floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management

4 days ago

CME credits: 1.00Valid until: 25-04-2025Claim your CME credit at https://reachmd.com/programs/cme/on-the-clinic-floor-addressing-the-most-critical-questions-of-frontline-clinicians-in-multiple-sclerosis-management/16629/The field of

Idiopathic Pulmonary Fibrosis: The Role of Radiology in Accurate and Timely Diagnosis

4 days ago

CME credits: 1.00Valid until: 07-11-2024Claim your CME credit at https://reachmd.com/programs/clinicians-roundtable/idiopathic-pulmonary-fibrosis-the-role-of-radiology-in-accurate-and-timely-diagnosis/18077/Learn from experts about

Managing Indolent Systemic Mastocytosis: A Multidisciplinary Case Review

5 days ago

Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM).

Multidisciplinary Approach to Diagnosing and Managing Indolent Systemic Mastocytosis: The Changing Landscape

5 days ago

Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD Guest: Matthew J. Hamilton, MD Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-

Managing Indolent Systemic Mastocytosis: A Multidisciplinary Case Review

5 days ago

CME credits: 0.50Valid until: 24-04-2025Claim your CME credit at https://reachmd.com/programs/cme/managing-indolent-systemic-mastocytosis-a-multidisciplinary-case-review/18089/New tyrosine kinase inhibitor (TKI) treatment options ca

Diagnosing ATTRv-PN: What's in Your Toolbox?

6 days ago

Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore